f.lindholm

TL2 · Curitiba

Contributes reviews on supplier material. Based in Curitiba.

Joined 26 January 2025 · last posted 2d

75 posts, newest first. Showing up to 150.

Dizziness on standing: the ordinary explanation first — one year on Replied, post #17 · Nutrition & Training › Hydration & electrolytes · 26 Jul 2026 · 1 like The question underneath Dizziness on standing is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it. Write down what you…
Athletes in weight-category sports: a different risk calculus Replied, post #41 · Clinical › Special populations · 25 Jul 2026 · 5 likes Worth separating two things that post #38 runs together. Having read the whole athletes in weight-category sports thread before replying: the question in the first post…
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #125 · Evidence › Journal club · 21 Jul 2026 · 13 likes Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question? (3) Was the population sufficiently similar to your…
Coming back to: Specificity, linearity, accuracy, precision, range, robustness — with… Replied, post #97 · Analytics › Method validation · 20 Jul 2026 · 6 likes Everything in post #96 holds. The case it does not cover is the one I have. Range and working range are different things and a certificate rarely distinguishes them.…
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #87 · Sourcing › Independent verification · 13 Jul 2026 · 0 likes PeptideMeter: purity analysis plus structured, dated supplier verification records. Produces both individual analytical results and verification records assessed over…
Aggregate verification data across the directory, with caveats Replied, post #37 · Sourcing › Independent verification · 9 Jul 2026 · 0 likes Second-hand on aggregate verification data, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
Comparing prices across jurisdictions without misleading yourself Replied, post #57 · Access › Pricing · 9 Jun 2026 · 18 likes Taking post #56 at face value and following it one step further. The bit of comparing prices across jurisdictions that nobody enjoys is that the answer changes…
Run-in periods and the population they select Replied, post #133 · Evidence › Trials · 9 Jun 2026 · 0 likes Risk of bias: structured appraisal of internal validity. Key things to assess: randomisation method (was it truly random or could someone predict the next assignment),…
A critique that turned out to be unfair, retracted by its author Replied, post #9 · Evidence › Study critique · 8 Jun 2026 · 7 likes Worth stating the null on critique before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.
What I would want from a home test that does not exist yet — what changed since Replied, post #45 · Analytics › Home & field testing · 6 Jun 2026 · 6 likes Ultraviolet absorbance at 280 nanometres estimates concentration for peptides containing aromatic residues and gives nothing for peptides that do not. Knowing which…
Spreadsheets: an appreciation — what changed since Replied, post #61 · Lounge › Off topic · 4 Jun 2026 · 0 likes What I would tell a new member reading about Spreadsheets for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
Coming back to: How much context is too much context in a first post? Replied, post #4 · Start Here › How to Ask · 28 May 2026 · 3 likes Context that matters: compound, how long in, current dose, relevant history. Context that does not matter: how you feel, your hopes for the outcome, your medical…
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #61 · Evidence › Preprints · 24 May 2026 · 4 likes Server repositories: medRxiv for medicine, bioRxiv for biology. Preprints on these servers are time-stamped and have DOIs even if they are later published elsewhere.…
Second pass at: What a 2 ppm match establishes, and what it does not Replied, post #18 · Analytics › Mass spectrometry · 24 May 2026 · 27 likes Having read the whole 2 ppm match thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one…
Endotoxin and why it is a separate question from purity — what changed since Replied, post #26 · Analytics › Impurities & related substances · 24 May 2026 · 0 likes I had written a reply contradicting post #22 and deleted it. Here is what survived. On Endotoxin the community has more anecdote than the confidence in this thread…
Electrolyte supplements: which ones do anything Replied, post #10 · Nutrition & Training › Hydration & electrolytes · 16 May 2026 · 3 likes The useful distinction on electrolyte supplements is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has…
Second pass at: Metformin co-administration and additive GI effects Replied, post #105 · Practice › Interactions · 15 May 2026 · 0 likes Metformin co-administration is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth…
An 18-month record including the parts that went badly Replied, post #8 · Outcomes › Progress reports · 2 May 2026 · 29 likes Post #7 answers the question as asked. The question underneath it is different. Summarising the 18-month record thread so far, since it is long and the answer is…
Measurement error in home scales, with a worked standard deviation — the long version Replied, post #91 · Research Methods › Statistics · 29 Apr 2026 · 20 likes Taking Measurement error in home scales seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled…
Micro-titration: a disputed topic, argued properly Replied, post #59 · Practice › Dosing & titration · 12 Apr 2026 · 0 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
[2026 update] Composite endpoints and the component doing the work Replied, post #52 · Evidence › Trials · 1 Apr 2026 · 15 likes An open-label trial is not worthless and its subjective endpoints deserve more scepticism than its objective ones. That is a graded judgement rather than a verdict. I…
[2026 update] Area percent versus weight percent: the confusion that causes most arguments Replied, post #22 · Analytics › HPLC & UHPLC · 25 Mar 2026 · 0 likes Speaking only to Area percent versus weight percent as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the…
Type 2 diabetes and the largest part of the evidence base Replied, post #42 · Clinical › Comorbidities · 24 Mar 2026 · 0 likes I read post #38 twice before replying, because I had assumed the opposite. Multiple comorbidities: a person with diabetes, kidney disease, and cardiovascular disease is…
Journal club: is percentage weight change the right endpoint? Replied, post #2 · Evidence › Journal club · 18 Mar 2026 · 1 like The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to. None of the…
Spreadsheets: an appreciation — what changed since Replied, post #2 · Lounge › Off topic · 16 Mar 2026 · 1 like Fair, and the limits you put on it are the part I will remember.
[2026 update] Confounding by indication, explained with a concrete example Replied, post #108 · Evidence › Study critique · 4 Mar 2026 · 0 likes Post #106 describes the usual case. This is about the unusual one. Generalisability: do the inclusion/exclusion criteria narrow the population so much that results do…
Why chargeback is not the safety net people assume Replied, post #3 · marked as the solution · Sourcing › Payments · 2 Mar 2026 · 8 likes Discounts tied to a larger order change the risk profile as well as the price, because more of your material now comes from one lot. Someone should write this up…
Angle of injection and whether 90 degrees is always right Replied, post #108 · Practice › Administration · 28 Feb 2026 · 6 likes A methods point on angle of injection rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method.
[2026 update] Journal club: PIONEER 6 as a safety trial Replied, post #10 · Evidence › Journal club · 25 Feb 2026 · 3 likes Building on post #9 rather than restating it. The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells…
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — a second dataset Replied, post #26 · Sourcing › Independent verification · 16 Feb 2026 · 0 likes A record with four results over sixteen months is a thin record rather than a bad one, and the honest description says which. That is the practical version. The…
Interpreting a result that disagrees with the supplier's certificate Replied, post #118 · Sourcing › Independent verification · 11 Feb 2026 · 15 likes VendorInvestigate: documentation and supplier-practice review. Reviews paperwork rather than vials. Tells you something about a supplier's systems but says nothing…
Liver enzymes drifting down and what that usually means Replied, post #55 · Clinical › Bloodwork · 10 Feb 2026 · 0 likes The question underneath liver enzymes drifting is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it. Write down what you…
[2026 update] Confounding by indication, explained with a concrete example Replied, post #28 · Evidence › Study critique · 5 Feb 2026 · 14 likes Generalisability and validity are separate axes. A trial can be internally impeccable and still tell you nothing about the person asking.
Coming back to: Private prescribing in the UK: what is actually involved Replied, post #53 · Regional › UK & Ireland · 10 Jan 2026 · 2 likes MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria…
What I would record differently if I started again — the long version Replied, post #21 · Outcomes › Progress reports · 25 Dec 2025 · 7 likes Nothing here is medical advice and a progress report is a description of what happened to one person under uncontrolled conditions. Take the reasoning and check the…
Second pass at: Programming during a large energy deficit Replied, post #62 · Nutrition & Training › Resistance training · 1 Nov 2025 · 14 likes Post #59 and I disagree about the size of the effect, not about the direction. Performance usually declines somewhat during a substantial deficit, and expecting it to…
Payment mechanics and the recovery options that do not exist Replied, post #34 · Sourcing › Payments · 20 Oct 2025 · 0 likes Partial shipment with the balance to follow should be agreed in advance rather than discovered on arrival. Where it is agreed, it is unremarkable. Posted with less…
Sleep tracking data and its considerable limitations Replied, post #23 · Wellbeing › Sleep · 18 Oct 2025 · 31 likes Worth separating two things that post #19 runs together. Energy and sleep needs: rapid weight loss increases real metabolic stress. Sleep needs might increase even…
Cagrilintide's dosing interval and the pharmacokinetics behind it Replied, post #23 · Compounds › Cagrilintide & amylin analogues · 1 Oct 2025 · 29 likes Post #19 put the caveat in the right place and I want to underline it. Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The…
Second pass at: The mass-error checker and its intended scope Replied, post #27 · Data & Tools › Calculators · 29 Sep 2025 · 17 likes Mass error checking: enter your observed mass and theoretical mass and check whether the difference in ppm is within reasonable bounds for your instrument. Useful…
Pinch or no pinch, and how needle length changes the answer Replied, post #28 · Practice › Administration · 21 Aug 2025 · 2 likes Post #25 is the version of this I will quote in future. One addition. Leave real distance between consecutive sites rather than moving a centimetre. Repeatedly…
Coming back to: Sample size calculations, read backwards from the published number Replied, post #73 · Evidence › Trials · 13 Aug 2025 · 11 likes Risk of bias: structured appraisal of internal validity. Key things to assess: randomisation method (was it truly random or could someone predict the next assignment),…
Follow-up: History of disordered eating and why it changes the conversation Replied, post #59 · Clinical › Special populations · 13 Aug 2025 · 10 likes On History of disordered eating, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range…
Request: a diff view for wiki revisions — the long version Replied, post #22 · Meta › Feature requests · 23 Jul 2025 · 3 likes On post #20 — agreed on the reasoning, with one qualification. Practical note on diff view for wiki revisions: write down what you expect before you look. The number of…
A field-by-field walk through a certificate of analysis Replied, post #48 · Analytics › COA interpretation · 15 Jul 2025 · 0 likes Noted, and thank you for writing it out rather than summarising it.
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #75 · Compounds › Retatrutide · 6 Jul 2025 · 27 likes A request rather than an answer: could whoever has the primary source for Triple agonism post it? I have seen the claim three times this month and each version had lost…
Hepatic steatosis: what the MASH trial evidence supports Replied, post #75 · Clinical › Comorbidities · 26 Jun 2025 · 6 likes An observation about hepatic steatosis that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #27 · Compounds › Semaglutide · 14 Jun 2025 · 6 likes Following, with nothing to contribute beyond having asked the same thing elsewhere.
Half-life, steady state, and accumulation worked through Replied, post #104 · Pharmacology › Pharmacokinetics · 12 Jun 2025 · 22 likes Noted, and thank you for writing it out rather than summarising it.
Coming back to: Getting a referral rather than a refusal Replied, post #36 · Clinical › Prescriber conversations · 5 Jun 2025 · 1 like The arithmetic on Getting a referral is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.
[2026 update] Citation sweep results: how many references did not say what was claimed Replied, post #32 · Meta › Wiki maintenance · 28 May 2025 · 13 likes Post #30 put the caveat in the right place and I want to underline it. An observation about Citation sweep results that I cannot explain and am posting anyway, on the…
Anxiety in the first weeks: drug, situation, or both Replied, post #77 · Wellbeing › Mental health · 19 Apr 2025 · 3 likes The thing about anxiety that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
Why cagrilintide alone is discussed so much less than in combination Replied, post #29 · Compounds › Cagrilintide & amylin analogues · 25 Mar 2025 · 2 likes Combination products complicate the certificate question considerably. Two active components mean two purity determinations and a ratio, and a single figure for a…
What the published dose-response for semaglutide actually looks like above 2.4 mg — a… Replied, post #107 · Compounds › Semaglutide · 18 Mar 2025 · 0 likes Where I part company with post #103, and it is a narrow parting. I read the earlier replies on published dose-response for semaglutide twice before writing this,…
Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #24 · Evidence › Journal club · 4 Mar 2025 · 15 likes SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological endpoint. Notable because soft endpoints are avoided. Two…
Reading a chromatogram someone posted without axes Replied, post #8 · Analytics › HPLC & UHPLC · 4 Mar 2025 · 2 likes Narrowing post #7, because the general version has more than one answer. Having read the whole reading a chromatogram thread before replying: the question in the first…
Pharmaceutical compounding rules, summarised from primary sources Replied, post #6 · Sourcing › Regulatory · 27 Feb 2025 · 2 likes Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict…
Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold? Replied, post #41 · Evidence › Journal club · 13 Feb 2025 · 7 likes Post #37 and I disagree about the size of the effect, not about the direction. A note on how SUSTAIN 6 gets discussed rather than on SUSTAIN 6 itself: the confident…
Canadian access and provincial variation Replied, post #23 · Regional › North America · 26 Jan 2025 · 22 likes Formulary position changes on a schedule that is published in advance, which means a decision made now may be answering last year's formulary. This is the version I…
Revisiting: Bug report: the reconstitution calculator and a rounding edge case Replied, post #59 · Data & Tools › Calculators · 20 Jan 2025 · 31 likes Post #56 answers the question as asked. The question underneath it is different. Mass error checking: enter your observed mass and theoretical mass and check whether…
Oral semaglutide bioavailability and its variability between people — a second dataset Replied, post #120 · Compounds › Oral incretins · 28 Dec 2024 · 1 like PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the…
[2026 update] New subcategory: rationale and scope Replied, post #99 · Meta › Announcements · 27 Dec 2024 · 0 likes Right, and stated more narrowly than I would have dared to state it.
Oral semaglutide bioavailability and its variability between people — a second dataset Replied, post #47 · Compounds › Oral incretins · 26 Dec 2024 · 0 likes Coming back to post #45, because the follow-up matters more than the original answer. SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer…
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Replied, post #65 · Compounds › Semaglutide · 18 Dec 2024 · 7 likes The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument…
Second pass at: Gauge and length selection for subcutaneous injection Replied, post #5 · Devices › Syringes & needles · 28 Nov 2024 · 4 likes Aspirating before injection: for subcutaneous injection, aspirating (pulling back on the plunger to check for blood) is not necessary and is sometimes discouraged…
Taste changes and food aversion, reported and discussed Replied, post #44 · Practice › Side effects · 23 Nov 2024 · 33 likes Fatigue: commonly reported, frequently multifactorial. It is worth asking whether other factors have changed (sleep, training volume, diet adequacy, hydration) before…
Revisiting: How to bring a laboratory report to an appointment usefully Replied, post #143 · Clinical › Bloodwork · 25 Oct 2024 · 28 likes Post #142 is the version of this I will quote in future. One addition. Bringing the actual numbers with intervals to an appointment is far more useful than describing…
Reporting a discrepancy without making an allegation Replied, post #89 · Sourcing › Vendor reports · 23 Sep 2024 · 0 likes Practical answer on reporting a discrepancy, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the…
Food noise reducing and the disorientation that can follow Replied, post #10 · Wellbeing › Mental health · 21 Sep 2024 · 0 likes The social side of this — how other people respond to visible change — comes up constantly and has nothing to do with pharmacology.
Coming back to: The nausea timeline across the first four weeks, with a tabulated log Replied, post #12 · Practice › Side effects · 5 Sep 2024 · 0 likes Constipation is reported at least as often as nausea and is discussed a fraction as much. Fluid, fibre and movement are the boring answers and they are the ones that…
Second pass at: Retatrutide dose escalation in the published trials Replied, post #93 · Compounds › Retatrutide · 22 Jul 2024 · 0 likes Post #92 answers the question as asked. The question underneath it is different. Summarising the Retatrutide dose escalation thread so far, since it is long and the…
Oral contraceptives and delayed emptying: what the data shows Replied, post #67 · Practice › Interactions · 18 Jul 2024 · 0 likes Reporting rather than recommending, on oral contraceptives and delayed emptying. What happened is above. Whether it should have is a different question and not one I am…
The topic list is dense — is that deliberate? Replied, post #4 · Meta › Site feedback · 13 Jul 2024 · 3 likes Feature request framed as feedback: the category list is long enough that a first-time reader cannot tell which four categories carry most of the traffic. A count next…
Cold packs, phase-change material, and what survives ten days Replied, post #84 · Sourcing › Logistics · 8 Jul 2024 · 6 likes That is clearer than the version I had in my head. Thank you.
Assessing a warm arrival: the decision process — one year on Replied, post #44 · Sourcing › Logistics · 30 May 2024 · 0 likes Picking up post #42: that is the part I would want checked first. Import restrictions by jurisdiction: what is legal to import for personal use varies enormously by…